Want to see GB:EKF full AI Analyst Report?
Top Page
EKF Diagnostics Holdings
(LSE:EKF)
Select Model
Select Model
Rating:59Neutral
Price Target:
27.00 p
â–²(5.06% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily supported by financial resilience—low leverage and generally solid cash generation—offset by weaker/inconsistent profitability and a very high P/E valuation. Technical indicators are broadly neutral with slightly negative momentum, adding only modest support.
Positive Factors
Conservative balance sheet
Very low leverage and sizable equity materially reduce financial risk and preserve optionality. This conservatism supports sustained R&D, regulatory approvals and targeted M&A, and provides a multi‑month buffer to absorb operational shocks without needing urgent external financing.
Negative Factors
Revenue volatility and reduced scale
Material revenue swings over recent years reduce predictability of consumable pull‑through and make capacity planning harder. The loss in scale versus earlier peaks weakens negotiating leverage with suppliers and distributors and raises execution risk for restoring durable top‑line growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and sizable equity materially reduce financial risk and preserve optionality. This conservatism supports sustained R&D, regulatory approvals and targeted M&A, and provides a multi‑month buffer to absorb operational shocks without needing urgent external financing.
Read all positive factors
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£111.89M
Dividend YieldN/A
Average Volume (3M)597.80K
Price to Earnings (P/E)54.1
Beta (1Y)0.22
Revenue Growth2.73%
EPS Growth-65.94%
CountryUK
Employees301
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding430,333,100
10 Day Avg. Volume853,279
30 Day Avg. Volume597,798
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.71
Price to Sales (P/S)2.30
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)£54.60M
EKF Diagnostics Holdings Business Overview & Revenue Model
Company Description
EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of dia...
How the Company Makes Money
EKF primarily makes money through the sale of diagnostic products, combining (1) instrument/equipment revenue and (2) recurring consumables revenue. Instrument revenue comes from selling diagnostic analyzers (point-of-care and/or laboratory instru...
EKF Diagnostics Holdings Earnings Call Summary
Earnings Call Date:Sep 16, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 22, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with notable revenue and profit growth, increased production capacity, and successful new contracts. However, there were challenges in the APAC region and some market constraints affecting the share buyback program. Overall, the positives, including significant production increases and strategic growth plans, outweigh the negatives.Positive Updates
Revenue and Profit Growth
Revenues for the first half were GBP 25.2 million, in line with the previous year, but closer to GBP 26 million on a constant currency basis. Gross profit improved with a gross margin increase to 50% from 48%. EBITDA grew by 7.4% to GBP 5.8 million, and profit increased by 16.1%.
Negative Updates
Decline in APAC Region
A 26% drop in the APAC region, primarily due to discontinued products in clinical chemistry.
Read all updates
Q2-2025 Updates
Positive
Negative
Revenue and Profit Growth
Revenues for the first half were GBP 25.2 million, in line with the previous year, but closer to GBP 26 million on a constant currency basis. Gross profit improved with a gross margin increase to 50% from 48%. EBITDA grew by 7.4% to GBP 5.8 million, and profit increased by 16.1%.
Read all positive updates
Company Guidance
During the investor presentation, EKF Diagnostics reported a stable revenue of GBP 25.2 million for the first half of 2025, aligning with the previous year, but noted a rise to GBP 26 million on a constant currency basis. The company improved its gross margin from 48% to 50% by eliminating lower-margin products, resulting in a 7.4% increase in EBITDA to GBP 5.8 million and a 16.1% rise in profit. They also highlighted a cash reserve increase to GBP 16.6 million, aiming to reach GBP 20 million by year-end. Production capacity was a focal point, with hematology analyzer production up by 60%, anticipating substantial consumable growth in the latter half of 2025. Strategic expansions included signing contracts in Africa and Latin America, contributing to a 12% increase in Beta-Hydroxybutyrate sales. Additionally, EKF executed a share buyback, purchasing 4.6 million shares to enhance earnings per share, and maintained a focus on its 5-year strategy for sustainable growth and increasing revenue and EBITDA by 2029.EKF Diagnostics Holdings Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
83
Very Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.56M | 50.19M | 52.61M | 66.64M | 81.84M |
| Gross Profit | 26.48M | 21.48M | 23.86M | 24.04M | 39.37M |
| EBITDA | 12.40M | 11.16M | 7.68M | -2.18M | 27.39M |
| Net Income | 2.12M | 6.24M | 2.35M | -10.10M | 15.85M |
Balance Sheet | |||||
| Total Assets | 81.14M | 81.75M | 80.85M | 89.29M | 115.12M |
| Cash, Cash Equivalents and Short-Term Investments | 15.83M | 13.01M | 6.02M | 11.58M | 20.34M |
| Total Debt | 1.39M | 1.32M | 4.10M | 1.55M | 3.47M |
| Total Liabilities | 10.86M | 8.53M | 12.63M | 14.77M | 20.38M |
| Stockholders Equity | 69.05M | 72.33M | 67.12M | 73.35M | 94.12M |
Cash Flow | |||||
| Free Cash Flow | 8.18M | 11.41M | -664.00K | 3.86M | 4.59M |
| Operating Cash Flow | 9.71M | 13.66M | 6.31M | 9.69M | 10.24M |
| Investing Cash Flow | -2.34M | -2.66M | -5.64M | -8.93M | -5.48M |
| Financing Cash Flow | -5.86M | -4.08M | -3.65M | -11.04M | -6.16M |
EKF Diagnostics Holdings Technical Analysis
Negative
25.70
Price Trends
25.92
Negative
25.65
Negative
25.58
Negative
Market Momentum
-0.08
Negative
45.98
Neutral
55.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EKF, the sentiment is Negative. The current price of 25.7 is above the 20-day moving average (MA) of 25.66, below the 50-day MA of 25.92, and above the 200-day MA of 25.58, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 55.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EKF.
EKF Diagnostics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £78.90M | 10.56 | 65.83% | 9.84% | -8.21% | -5.27% | |
59 Neutral | £111.89M | 54.15 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.28M | 3.25 | 12.15% | ― | -10.20% | 714.29% | |
50 Neutral | £26.54M | -12.50 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £19.27M | -1.06 | -1044.57% | ― | 65.60% | 74.84% | |
45 Neutral | £16.17M | -0.33 | -631.25% | ― | ― | ― |
* Healthcare Sector Average
GB:EKF
EKF Diagnostics Holdings
25.45
-3.90
-13.29%
GB:BVXP
Bioventix
1,500.00
-717.11
-32.34%
GB:GDR
Genedrive
1.15
0.21
22.47%
GB:CNSL
Omega Diagnostics
1.85
-1.65
-47.14%
GB:RENX
Renalytix
4.55
-1.70
-27.20%
GB:ABDX
Abingdon Health PLC
10.50
4.25
68.00%
EKF Diagnostics Holdings Corporate Events
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 100,000 Shares in New Buyback Move
Positive
Aug 6, 2026
EKF Diagnostics Holdings has repurchased 100,000 of its ordinary shares at a weighted average price of 25.3p per share and will cancel them, reducing its issued share capital. The move reflects active capital management by the AIM-listed diagnosti...
Business Operations and StrategyStock Buyback
EKF Diagnostics Cancels 110,000 Shares in Targeted Buyback
Positive
Aug 5, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 110,000 ordinary shares at a price of 25.5p each and cancelling them, leaving 429,433,112 shares in issue and none held in treasury. The move reduces the company’s share count...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 40,000 Shares in Targeted Buyback
Positive
Aug 4, 2026
EKF Diagnostics has executed a share buyback, purchasing 40,000 ordinary shares at a weighted average price of 25.3p per share and cancelling them to reduce its share capital. Following this transaction, the company’s issued share capital st...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 80,000 Shares in Targeted Buyback
Positive
Aug 3, 2026
EKF Diagnostics Holdings has undertaken a share buyback, purchasing 80,000 ordinary shares at a weighted average price of 25.5p per share, with the shares to be cancelled. Following this transaction, the company’s issued share capital will c...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
EKF Diagnostics trims share count with 100,000-share buyback
Positive
Jul 31, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 100,000 ordinary shares at a weighted average price of 25.42p and cancelling them, in a move that reduces its outstanding share count. Following the cancellation, the company’...
Business Operations and StrategyStock Buyback
EKF Diagnostics Cancels 100,000 Shares After Targeted Buyback
Positive
Jul 31, 2026
EKF Diagnostics Holdings plc, an AIM-listed global diagnostics firm, focuses on point-of-care analysers in hematology and diabetes and provides life sciences services that manufacture specialist enzymes and custom products for diagnostic, food and...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 150,000 Shares After Buyback
Neutral
Jul 30, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 150,000 ordinary shares at a price of 25.5 pence per share, with the shares to be cancelled. Following this transaction, the company’s issued share capital will consist of 429...
Business Operations and StrategyStock BuybackFinancial Disclosures
EKF Diagnostics lifts margins and cash as Life Sciences drives H1 2026 growth
Positive
Jul 30, 2026
EKF Diagnostics reported that first-half 2026 trading was in line with expectations, with revenue broadly flat at £25.0m but gross margin improving to 53% and adjusted EBITDA continuing to grow. The group ended the period with £16.0m in ...
Business Operations and StrategyStock Buyback
EKF Diagnostics cancels shares after targeted buyback on AIM
Positive
Jul 27, 2026
EKF Diagnostics Holdings plc has executed a share buyback, purchasing 60,000 ordinary shares at a weighted average price of 25.1932 pence, with all acquired shares to be cancelled. The transaction was carried out on 24 July 2026 on AIMX and forms ...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 50,000 Shares in Targeted Buyback
Positive
Jul 17, 2026
EKF Diagnostics Holdings, the AIM-listed global diagnostics business, has executed a share buyback of 50,000 ordinary shares at a weighted average price of 25.5 pence, with all repurchased shares to be cancelled. Following this transaction, the co...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cuts Share Count with 100,000-Share Buyback
Positive
Jul 16, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 100,000 ordinary shares at a weighted average price of 25.5 pence per share, with all repurchased shares to be cancelled. The transactions, carried out on the AIM market, form part ...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics cancels 150,000 shares in latest buyback
Positive
Jul 15, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 150,000 ordinary shares at a weighted average price of 25.5 pence per share, with all repurchased shares to be cancelled. Following this transaction and cancellation, the company...
Business Operations and StrategyStock Buyback
EKF Diagnostics Cancels 60,000 Shares in Modest Buyback
Positive
Jun 15, 2026
EKF Diagnostics Holdings has carried out a share buyback, purchasing 60,000 ordinary shares at a weighted average price of 25.0 pence per share, with all of the repurchased stock set to be cancelled. The move reduces the company’s share coun...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 50,000 Shares in Targeted Buyback
Positive
Jun 12, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 50,000 ordinary shares at a weighted average price of 24.8 pence per share, with the shares to be cancelled. Following this transaction, the company’s issued share capital wil...
Stock BuybackRegulatory Filings and Compliance
EKF Diagnostics Cancels 120,000 Shares in Latest Buyback
Positive
Jun 11, 2026
EKF Diagnostics Holdings has executed a share buyback, purchasing 120,000 ordinary shares at a weighted average price of 24.8 pence per share, with all repurchased shares to be cancelled. The move will reduce the company’s share count and ma...
Executive/Board Changes
EKF Diagnostics Grants Performance-Linked LTIP to New CFO
Positive
May 20, 2026
EKF Diagnostics Holdings has granted a long-term incentive plan award to its newly appointed chief financial officer, Helen Jones, in the form of a nominal cost option over 282,353 ordinary shares. The performance-based award runs for three years ...
Business Operations and StrategyShareholder Meetings
EKF Diagnostics Wins Strong Shareholder Backing at AGM
Positive
May 19, 2026
EKF Diagnostics Holdings said all resolutions put to shareholders at its latest Annual General Meeting were passed, reflecting strong investor support for the AIM-listed diagnostics group. The detailed voting results showed high approval rates acr...
Business Operations and StrategyStock BuybackFinancial DisclosuresShareholder Meetings
EKF Diagnostics posts solid Q1 and reaffirms 2026 guidance
Positive
May 19, 2026
EKF Diagnostics told shareholders ahead of its AGM that trading so far in 2026 is in line with management expectations, marking a solid start to the second year of its five-year strategic development plan. The company said it has simplified its pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.